← ANALYST RATINGS · TIPRANKS
Guardant Health (GH): analyst forecast and price target
Analyst consensus
Strong Buy19 Buy0 Hold0 Sell
Ratings of 19 analysts in the last 3 months12-month forecast
Based on 19 price targets given in the last 3 months, the average target is $203, the highest $225, the lowest $180. The average is +28.2% from the last price of $159.
Analyst ratings 26
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $195 | Buy | +23.0% | Reiterated | 14.10.26on TipRanks 06:35 | +1.6%next day +1.5% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $185 → $200+8.1% | Buy | +26.1% | Assigned | 12.10.26on TipRanks 09:30 | −2.7%next day −0.4% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $210 | Buy | +32.4% | Reiterated | 12.10.26on TipRanks 06:30 | −2.7%next day −0.4% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $195 → $200+2.6% | Buy | +26.1% | Reiterated | 09.10.26on TipRanks 08:25 | +0.6%next day −2.7% · 5 days −3.3% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $200 → $220+10.0% | Buy | +38.7% | Reiterated | 07.10.26on TipRanks 03:55 | −1.1%next day −1.2% · 5 days −2.2% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $190 → $200+5.3% | Buy | +26.1% | Reiterated | 01.10.26on TipRanks 08:35 | −2.2%next day +1.0% · 5 days −6.6% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $184 | Hold | +16.0% | Reiterated | 21.09.26on TipRanks 01:06 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $187 | Hold | +17.9% | Reiterated | 21.09.26on TipRanks 01:06 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $188 | Hold | +18.5% | Reiterated | 21.09.26on TipRanks 01:06 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $183 | Hold | +15.4% | Reiterated | 21.09.26on TipRanks 01:06 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $187 | Hold | +17.9% | Reiterated | 21.09.26on TipRanks 01:06 | — | |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $210 → $225+7.1% | Buy | +41.9% | Reiterated | 20.09.26on TipRanks Sep 21 08:15 | −4.6%next day +1.9% · 5 days +3.0% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | — | Buy | — | Reiterated | 15.09.26on TipRanks Sep 16 09:30 | +5.1%next day 0.0% · 5 days −1.5% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $193 | Buy | +21.7% | Reiterated | 15.09.26on TipRanks 07:45 | +5.1%next day 0.0% · 5 days −1.5% | ↗ |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $175 → $225+28.6% | Buy | +41.9% | Reiterated | 09.09.26on TipRanks Sep 14 09:30 | +1.6%next day −1.7% · 5 days +8.5% | ↗ |
| Jamie Clark★★★★★★★★★★#6680 · hits 75% · avg +5.9% | Rothschild & Co Redburn | $203 | Buy | +28.0% | Initiated | 08.09.26on TipRanks 05:20 | +0.3%next day +1.6% · 5 days +10.2% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 08.09.26on TipRanks 04:45 | +0.3%next day +1.6% · 5 days +10.2% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $195 | Buy | +23.0% | Reiterated | 01.09.26on TipRanks Sep 2 06:30 | +4.1%next day −1.3% · 5 days −1.1% | ↗ |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $158 → $167+5.7% | Hold | +5.3% | Reiterated | 20.08.26on TipRanks 01:06 | — | |
| Bradley Bowers★★★★★★★★★★#1314 · hits 90% · avg +72.1% | Mizuho Securities | $200 | Buy | +26.1% | Reiterated | 04.08.26on TipRanks 08:17 | −1.2%next day +2.3% · 5 days +3.4% | ↗ |
| Mason Carrico★★★★★★★★★★#10833 · hits 38% · avg −4.7% | Stephens | $195 | Buy | +23.0% | Reiterated | 04.08.26on TipRanks 07:56 | −1.2%next day +2.3% · 5 days +3.4% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $130 → $180+38.5% | Buy | +13.5% | Reiterated | 03.08.26on TipRanks 06:50 | −3.4%next day −1.2% · 5 days +3.2% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $205 | Buy | +29.3% | Reiterated | 02.08.26on TipRanks Aug 3 07:45 | −3.4%next day −1.2% · 5 days +3.2% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $185 → $200+8.1% | Buy | +26.1% | Assigned | 31.07.26on TipRanks 08:24 | +5.6%next day −3.4% · 5 days +0.5% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $200 → $210+5.0% | Buy | +32.4% | Assigned | 31.07.26on TipRanks 03:46 | +5.6%next day −3.4% · 5 days +0.5% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $150 → $215+43.3% | Buy | +35.6% | Reiterated | 08.07.26on TipRanks 06:50 | −3.8%next day +4.2% · 5 days +3.1% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $160 → $200+25.0% | Buy | +26.1% | Reiterated | 06.07.26on TipRanks 08:50 | −0.4%next day −3.0% · 5 days −5.9% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | — | Buy | — | Reiterated | 02.06.26on TipRanks Jun 4 22:25 | +0.7%next day −1.7% · 5 days +2.9% | ↗ |
| Paige Chamberlain★★★★★★★★★★#7338 · hits 100% · avg +13.9% | Wolfe Research | $120 → $150+25.0% | Buy | −5.4% | Assigned | 01.06.26on TipRanks Jun 2 06:15 | −0.7%next day +0.7% · 5 days −0.7% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $120 → $129+7.5% | Buy | −18.7% | Reiterated | 08.05.26on TipRanks 08:55 | +2.9%next day +0.8% · 5 days −1.0% | ↗ |
| Andrew Cooper★★★★★★★★★★#11107 · hits 40% · avg −3.0% | Raymond James | $129 | Buy | −18.7% | Reiterated | 23.02.26on TipRanks 09:40 | −7.4%next day +0.3% · 5 days −2.9% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $115 → $130+13.0% | Buy | −18.0% | Reiterated | 17.12.25on TipRanks Dec 16 08:45 | −2.3%next day −1.4% · 5 days +0.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Guardant Health
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $202 at a price of $178 (+13.3%); now: $203 at $159 (+28.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 1 | 0 | 0 | 0 |
| Buy | 32 | 40 | 64 | 50 | 53 | 28 |
| Hold | 2 | 2 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.75 (from $-0.90 to $-0.64). Last quarter: $-0.90.
Sales
Next quarter’s sales estimate — $351M (from $342M to $359M). Last quarter: $335M.
Best top-analyst consensus in the sector · Healthcare
About Guardant Health
- CEO: Helmy Eltoukhy
- Employees: 2,498
- 3100 Hanover Street, Palo Alto, CA, 94304, US
- guardanthealth.com
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Data from the stock’s TipRanks forecast page, read 37 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗